SpringWorks Therapeutics Inc Cash Flow Conversion Efficiency
SpringWorks Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, SpringWorks Therapeutics Inc (SWTX) has a cash flow conversion efficiency ratio of -0.165x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-68.76 Million) by net assets ($417.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SpringWorks Therapeutics Inc (2000–2024)
Cash flow conversion efficiency of SpringWorks Therapeutics Inc from 2000 to 2024. This chart illustrates how SpringWorks Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SpringWorks Therapeutics Inc stock price for real-time trading data and today's change.
SpringWorks Therapeutics Inc Cash Flow Conversion Ratio Explained
SpringWorks Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SpringWorks Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SpringWorks Therapeutics Inc ranked by their cash flow conversion efficiency. Also see how much is SpringWorks Therapeutics Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yantai Moon Co Ltd
SHE:000811
|
0.046x |
|
Suzhou Novosense Microelectronics Co. Ltd.
SHG:688052
|
-0.026x |
|
Zhejiang Yinlun Machinery Co Ltd
SHE:002126
|
0.037x |
|
Shanghai Moons' Elec Co Ltd
SHG:603728
|
0.020x |
|
Jiangsu Leadmicro Nano Technology Co. Ltd. A
SHG:688147
|
N/A |
|
HNI Corp
NYSE:HNI
|
-0.018x |
|
Aedifica
BR:AED
|
0.000x |
|
Kinetik Holdings Inc
NYSE:KNTK
|
0.063x |
Annual Cash Flow Conversion Efficiency for SpringWorks Therapeutics Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of SpringWorks Therapeutics Inc from 2000 to 2024. Review SpringWorks Therapeutics Inc (SWTX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $481.10 Million | $-175.60 Million | -0.365x | -2.59% |
| 2023-12-31 | $626.22 Million | $-222.79 Million | -0.356x | -22.92% |
| 2022-12-31 | $558.19 Million | $-161.56 Million | -0.289x | +4.39% |
| 2021-12-31 | $422.40 Million | $-127.88 Million | -0.303x | -423.89% |
| 2020-12-31 | $557.06 Million | $-32.19 Million | -0.058x | +60.77% |
| 2019-12-31 | $322.07 Million | $-47.44 Million | -0.147x | -119.40% |
| 2018-12-31 | $-19.37 Million | $-14.71 Million | 0.759x | -10.99% |
| 2017-12-31 | $-2.62 Million | $-2.24 Million | 0.853x | +460.05% |
| 2010-12-31 | $36.81 Million | $5.61 Million | 0.152x | -20.90% |
| 2009-12-31 | $27.15 Million | $5.23 Million | 0.193x | -41.95% |
| 2008-12-31 | $21.41 Million | $7.10 Million | 0.332x | -2.79% |
| 2007-12-31 | $16.69 Million | $5.70 Million | 0.341x | +440.29% |
| 2006-12-31 | $11.85 Million | $748.00K | 0.063x | -74.88% |
| 2005-12-31 | $15.94 Million | $4.01 Million | 0.251x | -4.37% |
| 2004-12-31 | $14.57 Million | $3.83 Million | 0.263x | -49.59% |
| 2001-12-31 | $26.45 Million | $13.79 Million | 0.521x | +561.99% |
| 2000-12-31 | $20.14 Million | $1.59 Million | 0.079x | -- |
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor o… Read more